Compass says COMP360 NDA will be filed within two weeks
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
Compass Pathways said in its Q3 2026 results that its new drug applicationNDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary for COMP360 psilocybin for treatment-resistant depressiontreatment-resistant depressionDepression that has not improved enough after adequate courses of at least two antidepressant treatments.Open the glossary (TRD) is nearing completion and will be filed in the next two weeks. The release describes the final NDA submission as nearing completion. The company declined to comment on Usona.
Key facts
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Compass Pathways
- Source
- Psychedelic Alpha (psychedelicalpha.com)
- Published
- Original
- Read it at psychedelicalpha.com
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: Psychedelic Alpha · psychedelicalpha.com
Connected to
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Compass Pathways